Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.43 |
| ▸ | PRSS8 | Q16651 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 2/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7046968 | 0.94 | ELANE (0.44) | ELANEPRSS8ATMXDHSLC1A3 | |
| SCHEMBL7046461 | 0.92 | ELANE (0.43) | ELANEPRSS8ATMXDHSLC1A3 | |
| SCHEMBL7049761 | 0.88 | ELANE (0.46) | ELANEPRSS8XDHSLC1A3SLC1A1 | |
| SCHEMBL6467567 | 0.88 | CTSS (0.38) | ELANEXDHMAPT | |
| SCHEMBL7049752 | 0.85 | KMT2A (0.43) | ELANEATMXDHSLC1A3SLC1A1 | |
| SCHEMBL6475534 | 0.83 | SMN1; SMN2 (0.39) | ELANEMAPT | |
| SCHEMBL7046281 | 0.81 | FAAH (0.41) | ELANEATMXDHSLC1A3SLC1A1 | |
| SCHEMBL6063445 | 0.79 | PTGER4 (0.47) | SLC1A3SLC1A1KCNA5 | |
| SCHEMBL7043362 | 0.79 | KCNA5 (0.39) | SLC1A3SLC1A1KCNA5 | |
| SCHEMBL7047104 | 0.78 | LMNA (0.45) | XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | ELANE 50/4885PRSS8 33/4885ATM 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.